Next Episode

Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?

Released Wednesday, 29th May 2019

Good episode? Give it some love!

Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?

Wednesday, 29th May 2019

Good episode? Give it some love!

Rate Episode

Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds. Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients.

Check out more of our content here:

Rate

Get this podcast via API

From The Podcast

Industry Focus

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at [email protected].

Join Podchaser to...

Rate podcasts and episodes
Follow podcasts and creators
Create podcast and episode lists
& much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.

Unlock more with Podchaser Pro

Audience Insights

Contact Information

Demographics

Charts

Sponsor History

and More!

Resources
Help Center
Blog
API

Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More